Navigation Links
Mouse gene shows new mechanism behind cardiac infarction in man

A gene that, in different variants, increases or decreases the level of atherosclerosis has been identified in mice. The corresponding human gene has been shown to play a role in the development of myocardial infarction.

The results of the study is published this week on Nature Genetics Online.

Researchers at Karolinska Institutet, in collaboration with the Jackson Laboratory in the USA, AstraZeneca and a Japanese research group, have scrutinised an area on chromosome 1 that is of demonstrable importance to the development of arteriosclerosis. The TNFSF4 gene was identified as the one responsible, as mice with mutations in this gene displayed a lower degree of atherosclerosis, while mice with more active variants of the gene displayed the opposite.

Studies of two patient groups revealed that a certain variant of the human homologue of the gene was more common in people who had a history of cardiac infarction than those without.

“This is an example of how an unbiased genetic strategy based on a mice model can teach us more about common human diseases,?says researcher Jacob Lagercrantz of the Gustav V research institute, Karolinska Institutet.

The gene codes for a protein called OX40L, which is involved in the activation of immunological T cells. These cells, in turn, play an important role in the pathogenesis of atherosclerosis and of a number of chronic inflammatory diseases. The new finding will spur further research into the relationship between the protein and cardiac infarction. Hopefully it will offer a new therapeutic technique for the treatment of atherosclerosis and thus reduce the risk of cardiac infarction.


'"/>

Source:News-Medical


Page: 1

Related biology news :

1. Mouse brain cells rapidly recover after Alzheimers plaques are cleared
2. Mouse brain tumors mimic those in human genetic disorder
3. Research Using Mouse Models Reveals A Novel Key Player In The Initiation Of Colon Cancer
4. Mouse with designer liver has enhanced glucose tolerance, insulin response
5. Agilent Technologies Introduces First Commercial Mouse Microarray for Comparative Genomic Hybridization Research
6. Mouse genome much more complex than expected
7. Mouse study: New muscle-building agent beats all previous ones
8. Mouse study reveals human X-SCID gene therapy poses substantial cancer risk
9. Mouse to man: The story of chromosomes
10. Mouse mimics chronic leukemia, will aid drug development
11. Mouse study reveals new clues about virulence of 1918 influenza virus
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:1/12/2017)... DIEGO , Jan. 12, 2017  Trovagene, Inc. ... tumor DNA (ctDNA) technologies, today announced that it has ... Europe and the Middle East ... tests.  This milestone marks the first wave of international ... for urine and blood samples. The initial ...
(Date:1/11/2017)... Johnson, co-founder of Visikol Inc. a company originally funded with an ... the elite "Forbes 30 Under 30" list in the Science category. ... fields nationwide to be recognized as a leader in business and ... ... PhD candidate at Rutgers University. Visikol , ...
(Date:1/4/2017)... , Jan. 4, 2017  For the thousands of attendees at this ... leader in connected health and biometric measurement devices and services, will be ... On display in A&D Medical,s special CES Exhibit Suite , ... ongoing expansion of the company,s WellnessConnected product platform.  ... ...
Breaking Biology News(10 mins):
(Date:1/18/2017)... ... January 18, 2017 , ... MYOLYN, which ... it has submitted a 510(k) to the FDA, requesting clearance of the MyoCycle ... electrical stimulation (FES) technology. , The submission marks a major milestone for ...
(Date:1/18/2017)... ... January 18, 2017 , ... DrugDev ... Summit for Clinical Ops Executives (Hyatt Regency Miami, January 24-26). DrugDev will join ... clinical research issues such as trial performance metrics, patient enrollment diversity, protocol optimization, ...
(Date:1/18/2017)... CA (PRWEB) , ... January 18, 2017 , ... ... report the publishing of the latest paper by its Science Editor, Dr. Elisabeth ... (Nederlands Tijdschrift voor Medische Microbiologie). Dr. Bik joined uBiome in October 2016 from ...
(Date:1/18/2017)... Jan. 18, 2017 Shareholder rights law firm ... whether the board members of CoLucid Pharmaceuticals, Inc. (NASDAQ: ... connection with the proposed sale of the Company to ... that develops small molecules for the acute treatment of ... it had signed a definitive merger agreement with Eli ...
Breaking Biology Technology: